Alterity Therapeutics Statistics
Total Valuation
Alterity Therapeutics has a market cap or net worth of 19.89 million. The enterprise value is 12.11 million.
| Market Cap | 19.89M |
| Enterprise Value | 12.11M |
Important Dates
The next estimated earnings date is Thursday, February 27, 2025.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +50.29% |
| Shares Change (QoQ) | +91.53% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 4.73B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.95 |
| EV / Sales | 4.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.44 |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.54 |
| Quick Ratio | 3.10 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -104.47% and return on invested capital (ROIC) is -66.27%.
| Return on Equity (ROE) | -104.47% |
| Return on Assets (ROA) | -52.66% |
| Return on Capital (ROIC) | -66.27% |
| Revenue Per Employee | 268,167 |
| Profits Per Employee | -1.28M |
| Employee Count | 10 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.18% in the last 52 weeks. The beta is 0.68, so Alterity Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -18.18% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 46.10 |
| Average Volume (20 Days) | 15,976 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alterity Therapeutics had revenue of 2.68 million and -12.76 million in losses. Loss per share was -0.00.
| Revenue | 2.68M |
| Gross Profit | 2.54M |
| Operating Income | -13.08M |
| Pretax Income | -12.73M |
| Net Income | -12.76M |
| EBITDA | -13.06M |
| EBIT | -13.08M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 8.43 million in cash and 106,115 in debt, giving a net cash position of 8.33 million.
| Cash & Cash Equivalents | 8.43M |
| Total Debt | 106,115 |
| Net Cash | 8.33M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.21M |
| Book Value Per Share | 0.00 |
| Working Capital | 9.12M |
Cash Flow
In the last 12 months, operating cash flow was -8.41 million and capital expenditures -3,818, giving a free cash flow of -8.41 million.
| Operating Cash Flow | -8.41M |
| Capital Expenditures | -3,818 |
| Free Cash Flow | -8.41M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 94.67% |
| Operating Margin | -487.82% |
| Pretax Margin | -474.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Alterity Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.29% |
| Shareholder Yield | -50.29% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Alterity Therapeutics has an Altman Z-Score of -15.68. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.68 |
| Piotroski F-Score | n/a |